Direct Impact

Concepts for which Shingo Kato has direct influence:

inflammatory bowel
zinc deficiency
predicting effectiveness
ulcerative colitis
uc- bingo
injection period
remission- induction

Prominent publications by Shingo Kato

KOL-Index: 2 Persistence and safety of switching ustekinumab maintenance therapy every 8 to 12 weeks in UC patients with clinical remission 26weeks and more.. Persistence and safety of switching ustekinumab maintenance therapy every 8 to 12 weeks in UC patients with clinical remission 26weeks and more.
KOL-Index: 2 Evaluation of the rate of clinical response and clinical remission in UC- patients refractory to conventional or infliximab and/ or adalimumab, and biomarkers of golimumab.. Evaluation of the rate of clinical response and clinical remission in UC- patients refractory to conventional or infliximab and/ or adalimumab, and biomarkers of golimumab.
KOL-Index: 2 Evaluation of clinical manifestation in IBD patients with serum zinc deficiency, as well as improvement of clinical activity and manifestation after zinc replacement therapy. Evaluation of clinical manifestation in IBD patients with serum zinc deficiency, as well as improvement of clinical activity and manifestation after zinc replacement therapy
KOL-Index: 2 To investigate biomarkers for predicting effectiveness of leukocyteapheresis, anti-TNF alpha antibody and tacrolimus for inflammatory bowel diseases. To investigate biomarkers for predicting effectiveness of leukocyteapheresis, anti-TNF alpha antibody and tacrolimus for inflammatory bowel diseases
KOL-Index: 2 Evaluation of vedolizumab-effects in prospective single-center cohort of IBD patients. Evaluation of vedolizumab-effects in prospective single-center cohort of IBD patients
KOL-Index: 2 Evaluation of ustekinumab and vedolizumab-effects in prospective single-center observational study in IBD, such as ulcerative colitis and Crohn's disease patients. Evaluation of ustekinumab and vedolizumab-effects in prospective single-center observational study in IBD, such as ulcerative colitis and Crohn's disease patients

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172